Omeros (OMER) EPS (Weighted Average and Diluted) (2019 - 2026)
Omeros recorded quarterly EPS (Weighted Average and Diluted) of $0.57 in Q1 2026, down 59.86% quarter-over-quarter from $1.42 in Q4 2025, and up 198.28% year-over-year from $0.19 in Q1 2025.
Omeros' EPS (Weighted Average and Diluted) history runs 8 years deep, the most recent figure standing at $0.57 for Q1 2026.
- In Q1 2026, EPS (Weighted Average and Diluted) rose 198.28% year-over-year to $0.57; the TTM figure through Mar 2026 stood at $1.09 (up 139.78% YoY), while the FY2025 annual figure was -$0.05, up 98.15% from the prior year.
- EPS (Weighted Average and Diluted) came in at $0.57 for Q1 2026 at Omeros, down from $1.42 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $1.42 in Q4 2025 to a low of -$0.97 in Q2 2024.
- A 5-year average of -$0.43 and a median of -$0.63 in 2022 frame the typical range for EPS (Weighted Average and Diluted).
- Across the five-year window, EPS (Weighted Average and Diluted) sank 141.67% in 2022 and soared 358.18% in 2025, its largest moves.
- Omeros' EPS (Weighted Average and Diluted) stood at -$0.73 in 2022, then grew by 19.18% to -$0.59 in 2023, then increased by 6.78% to -$0.55 in 2024, then jumped by 358.18% to $1.42 in 2025, then slumped by 59.86% to $0.57 in 2026.
- According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods registered $0.57, $1.42, and -$0.47 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 4.02 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 6.75 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.51 |
| 10 | Omeros | 772.03 Mn | 636.71 Mn | 9.31 Mn | 0.57 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.57 |
| Dec 31, 2025 | 1.42 |
| Sep 30, 2025 | -0.47 |
| Jun 30, 2025 | -0.43 |
| Mar 31, 2025 | -0.58 |
| Dec 31, 2024 | -0.55 |
| Sep 30, 2024 | -0.64 |
| Jun 30, 2024 | -0.97 |
| Mar 31, 2024 | -0.63 |
| Jun 30, 2023 | -0.59 |
| Mar 31, 2023 | -0.63 |
| Dec 31, 2022 | -0.73 |
| Sep 30, 2022 | -0.87 |
| Jun 30, 2022 | -0.66 |
| Mar 31, 2022 | -0.63 |
| Dec 31, 2021 | 5.44 |
| Sep 30, 2021 | -0.36 |
| Jun 30, 2021 | -0.46 |
| Mar 31, 2021 | -0.81 |
| Dec 31, 2020 | -1.21 |
| Sep 30, 2020 | -0.66 |
| Jun 30, 2020 | -0.61 |
| Dec 31, 2019 | -2.26 |